Loading...

APC/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK15_APCCyanine7_CD4_Antibody_020119
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD4 (clone GK1.5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
  • GK15_APCCyanine7_CD4_Antibody_020119
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD4 (clone GK1.5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100413 25 µg £60
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100414 100 µg £148
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  2. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  3. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  4. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  5. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  6. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  7. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
  8. Shao B, et al. 2018. Mol Med Rep. 18:920. PubMed
  9. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  10. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  11. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  12. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  13. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  14. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  15. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  16. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
  17. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  18. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  19. Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed
  20. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  21. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  22. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed
  23. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  24. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  25. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  26. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  27. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  28. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  29. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  30. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  31. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  32. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  33. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
  34. Ma C, et al. 2020. Sci Adv. 6:eaaz6717. PubMed
  35. Yeung F, et al. 2020. Cell Host & Microbe. 27(5):809-822. PubMed
  36. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  37. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  38. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  39. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  40. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  41. McNamee E, et al. 2013. Gut. 62:53. PubMed
  42. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  43. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
  44. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  45. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  46. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  47. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  48. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  49. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
  50. Ciarlo E, et al. 2016. Sci Rep. 6:37944. PubMed
  51. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  52. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  53. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  54. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  55. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  56. Sheng J, et al. 2021. eLife. 10:00. PubMed
  57. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  58. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  59. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  60. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  61. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  62. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  63. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  64. Dong L, et al. 2021. Cancer Cell. . PubMed
  65. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
  66. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  67. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  68. Gary E, et al. 2020. Vaccine. 3821:38. PubMed
  69. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  70. Levi J, et al. 2020. J Nucl Med. . PubMed
  71. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  72. Ma C, et al. 2021. J Exp Med. :218. PubMed
  73. Pandey S, et al. 2020. Cell Syst. 11:495. PubMed
  74. Saito S, et al. 2020. Nutrients. 12:. PubMed
  75. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  76. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  77. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
  78. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  79. Zhang L, et al. 2021. Clin Transl Med. 11:e464. PubMed
  80. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  81. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  82. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  83. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  84. Vasanthakumar A, et al. 2020. Nature. 579:581. PubMed
  85. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  86. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  87. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  88. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
  89. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  90. Wang X, et al. 2022. Elife. 11:. PubMed
  91. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  92. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  93. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  94. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  95. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  96. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
  97. Chen B, et al. 2021. Cell. 184:6262. PubMed
  98. Mara AB, et al. 2022. NPJ Vaccines. 7:86. PubMed
  99. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  100. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  101. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  102. Liu A, et al. 2022. Front Cell Infect Microbiol. 12:960208. PubMed
  103. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  104. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  105. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  106. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  107. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  108. Wang X, et al. 2021. Cell. 184:5357. PubMed
  109. Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed
  110. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  111. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  112. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  113. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  114. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  115. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  116. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  117. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  118. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  119. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  120. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  121. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  122. Campisi L, et al. 2022. Nature. 606:945. PubMed
  123. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  124. Molina MS, et al. 2022. PLoS One. 17:e0273075. PubMed
  125. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  126. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  127. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  128. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  129. Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed
  130. Agrafiotis A, et al. 2023. iScience. 26:106055. PubMed
  131. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  132. Ludwig J, et al. 2023. NPJ Vaccines. 8:52. PubMed
  133. Sun R, et al. 2023. PLoS One. 18:e0282722. PubMed
  134. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
RRID
AB_312698 (BioLegend Cat. No. 100413)
AB_312699 (BioLegend Cat. No. 100414)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 2    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account